-
Driving Therapeutic Innovation: Kifa Therapeutics and Parkinson's Research
Craig Lindsley, Executive Director of the Warren Center for Neuroscience Drug Discovery (WCNDD) and Christopher James, CEO and Founder of Kifa Therapeutics, have partnered to develop innovative treatments for Parkinson’s disease. -
Vanderbilt-Discovered Compound Advances to Phase 1 Clinical Trial as a Promising New Treatment for Schizophrenia
Neumora Therapeutics, Inc. has announced the launch of a Phase 1 clinical study evaluating NMRA-861 in healthy adult participants and adults with stable schizophrenia.